UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Cell (Cambridge), ISSN 0092-8674, 2010, Volume 140, Issue 3, pp. 327 - 337
HUMDISEASE | DEVBIO | SIGNALING | Biochemistry & Molecular Biology | Life Sciences & Biomedicine | Science & Technology | Cell Biology | Sperm Motility | Humans | Male | Spermatozoa - metabolism | Ion Channels - antagonists & inhibitors | Acrosome Reaction | Sperm Tail - metabolism | Animals | Ion Channels - metabolism | Sperm Capacitation | Female | Mice | Spermatozoa - cytology | Hydrogen-Ion Concentration | Spermatozoa | Index Medicus
Journal Article
Nature reviews. Clinical oncology, ISSN 1759-4774, 07/2013, Volume 10, Issue 7, pp. 390 - 399
Life Sciences & Biomedicine | Oncology | Science & Technology | Melanoma - metabolism | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Prognosis | Antineoplastic Agents - adverse effects | Humans | Melanoma - drug therapy | Cell Transformation, Neoplastic - chemically induced | Melanoma - pathology | Care and treatment | Gene mutations | Melanoma | Genetic aspects | Research | Health aspects | Risk factors | Index Medicus
Journal Article
Journal of investigative dermatology, ISSN 0022-202X, 12/2015, Volume 135, Issue 12, pp. 3115 - 3124
Life Sciences & Biomedicine | Dermatology | Science & Technology | Phosphoinositide-3 Kinase Inhibitors | Fibronectins - analysis | Humans | Proto-Oncogene Proteins c-akt - physiology | Melanoma - pathology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Transforming Growth Factor beta - pharmacology | Vemurafenib | Sulfonamides - therapeutic use | Melanoma - drug therapy | Cell Line, Tumor | Phosphatidylinositol 3-Kinases - physiology | Indoles - therapeutic use | Protein Kinase Inhibitors - pharmacology | Index Medicus | melanoma | fibroblasts | BRAF | resistance
Journal Article
Cancer research (Chicago, Ill.), ISSN 0008-5472, 04/2011, Volume 71, Issue 7, pp. 2750 - 2760
Life Sciences & Biomedicine | Oncology | Science & Technology | Tumors of the skin and soft tissue. Premalignant lesions | Dermatology | Pharmacology. Drug treatments | Biological and medical sciences | Medical sciences | Antineoplastic agents | Tumors | RNA, Small Interfering - genetics | Up-Regulation | Humans | Drug Resistance, Neoplasm | Phosphatidylinositol 3-Kinases - metabolism | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Proto-Oncogene Proteins - biosynthesis | Bcl-2-Like Protein 11 | Melanoma - genetics | Apoptosis Regulatory Proteins - genetics | Indoles - pharmacology | Proto-Oncogene Proteins c-akt - metabolism | Proto-Oncogene Proteins B-raf - metabolism | Apoptosis Regulatory Proteins - biosynthesis | Melanoma - metabolism | Proto-Oncogene Proteins - antagonists & inhibitors | PTEN Phosphohydrolase - deficiency | Membrane Proteins - genetics | PTEN Phosphohydrolase - biosynthesis | Proto-Oncogene Proteins - genetics | Melanoma - pathology | Sulfonamides - pharmacology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Membrane Proteins - biosynthesis | Membrane Proteins - antagonists & inhibitors | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Apoptosis Regulatory Proteins - antagonists & inhibitors | Cell Line, Tumor | Protein Kinase Inhibitors - pharmacology | Apoptosis - physiology | Mutation | RNA, Small Interfering - administration & dosage | Index Medicus | PTEN | melanoma | BRAF | PLX4032 | therapy | resistance
Journal Article
5.
Full Text
NRAS mutant melanoma: Biological behavior and future strategies for therapeutic management
Oncogene, ISSN 0950-9232, 06/2013, Volume 32, Issue 25, pp. 3009 - 3018
targeted therapy | Ras | melanoma | Biochemistry & Molecular Biology | Oncology | Genetics & Heredity | Life Sciences & Biomedicine | Science & Technology | Cell Biology | Melanoma - metabolism | Prognosis | Signal Transduction | Skin Neoplasms - therapy | Membrane Proteins - genetics | Humans | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Phosphatidylinositol 3-Kinases - metabolism | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Farnesyl-Diphosphate Farnesyltransferase - metabolism | Skin Neoplasms - metabolism | Mitogen-Activated Protein Kinase Kinases - metabolism | Farnesyl-Diphosphate Farnesyltransferase - antagonists & inhibitors | GTP Phosphohydrolases - genetics | Melanoma - genetics | Skin Neoplasms - genetics | Mutation | Melanoma - therapy | Proto-Oncogene Proteins B-raf - metabolism | Care and treatment | Ras genes | Gene mutations | Patient outcomes | Melanoma | Genetic aspects | Research | Health aspects | Risk factors | Proteins | Signal transduction | Disease management | Index Medicus
Journal Article
International journal of cancer, ISSN 0020-7136, 09/2016, Volume 139, Issue 6, pp. 1195 - 1201
leptomeninges | melanoma | BRAF | brain | immunotherapy | Life Sciences & Biomedicine | Oncology | Science & Technology | Melanoma - metabolism | Humans | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Meningeal Neoplasms - diagnosis | Melanoma - pathology | Molecular Targeted Therapy | Disease Progression | Meningeal Neoplasms - mortality | Meningeal Neoplasms - therapy | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Animals | Protein Kinase Inhibitors - therapeutic use | Immunotherapy | Disease Management | Protein Kinase Inhibitors - pharmacology | Biomarkers, Tumor - antagonists & inhibitors | Meningeal Neoplasms - secondary | Proto-Oncogene Proteins B-raf - metabolism | Development and progression | Metastasis | Melanoma | Medical prognosis | Index Medicus
Journal Article
Biochemical pharmacology, ISSN 0006-2952, 08/2011, Volume 82, Issue 3, pp. 201 - 209
Resistance | Vemurafenib | MEK | Melanoma | Cot | BRAF | MAPK | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Tumors of the skin and soft tissue. Premalignant lesions | Biological and medical sciences | Medical sciences | Dermatology | Pharmacology. Drug treatments | Melanoma - metabolism | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Melanoma - genetics | Proto-Oncogene Proteins B-raf - genetics | Humans | Antineoplastic Agents - pharmacology | Mutation | Gene Expression Regulation, Neoplastic - physiology | Proto-Oncogene Proteins B-raf - metabolism | Index Medicus | vemurafenib | melanoma | resistance
Journal Article
Oncogene, ISSN 0950-9232, 03/2016, Volume 35, Issue 10, pp. 1225 - 1235
Biochemistry & Molecular Biology | Oncology | Genetics & Heredity | Life Sciences & Biomedicine | Science & Technology | Cell Biology | Proto-Oncogene Proteins B-raf - deficiency | Cell Survival - drug effects | PTEN Phosphohydrolase - genetics | RNA, Small Interfering - genetics | PTEN Phosphohydrolase - deficiency | Humans | Myeloid Cell Leukemia Sequence 1 Protein - metabolism | Melanoma - pathology | Fibronectins - metabolism | Gene Knockdown Techniques | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Xenograft Model Antitumor Assays | Animals | Signal Transduction - drug effects | Proto-Oncogene Proteins B-raf - genetics | Proteomics | Cell Line, Tumor | Female | Mice | Protein Kinase Inhibitors - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Integrin alpha5beta1 - metabolism | Care and treatment | Gene mutations | Melanoma | Development and progression | Cellular signal transduction | Genetic aspects | Health aspects | Models | Gene expression | Proteins | Mutation | Cellular biology | Kinases | Index Medicus
Journal Article